These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3535490)

  • 1. Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.
    Ribeiro JP; White HD; Arnold JM; Hartley LH; Colucci WS
    Am J Med; 1986 Nov; 81(5):759-64. PubMed ID: 3535490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
    LeJemtel TH; Gumbardo D; Chadwick B; Rutman HI; Sonnenblick EH
    Circulation; 1986 Mar; 73(3 Pt 2):III213-8. PubMed ID: 3510777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure.
    White HD; Ribeiro JP; Hartley LH; Colucci WS
    Am J Cardiol; 1985 Jul; 56(1):93-8. PubMed ID: 4014048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute increase in exercise capacity with milrinone: lack of correlation with resting hemodynamic responses.
    Ribeiro JP; White HD; Hartley LH; Colucci WS
    Braz J Med Biol Res; 1990; 23(11):1069-78. PubMed ID: 2133014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
    Monrad ES; Baim DS; Smith HS; Lanoue AS; Silverman KJ; Gervino EV; Grossman W
    Circulation; 1986 Mar; 73(3 Pt 2):III205-12. PubMed ID: 3510776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
    Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
    Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with severe congestive heart failure treated with oral milrinone.
    Baim DS; Colucci WS; Monrad ES; Smith HS; Wright RF; Lanoue A; Gauthier DF; Ransil BJ; Grossman W; Braunwald E
    J Am Coll Cardiol; 1986 Mar; 7(3):661-70. PubMed ID: 3950244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
    Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
    N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.
    DiBianco R; Shabetai R; Kostuk W; Moran J; Schlant RC; Wright R
    N Engl J Med; 1989 Mar; 320(11):677-83. PubMed ID: 2646536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.
    Simonton CA; Chatterjee K; Cody RJ; Kubo SH; Leonard D; Daly P; Rutman H
    J Am Coll Cardiol; 1985 Aug; 6(2):453-9. PubMed ID: 4019930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
    Packer M; Carver JR; Rodeheffer RJ; Ivanhoe RJ; DiBianco R; Zeldis SM; Hendrix GH; Bommer WJ; Elkayam U; Kukin ML
    N Engl J Med; 1991 Nov; 325(21):1468-75. PubMed ID: 1944425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.
    Timmis AD; Smyth P; Jewitt DE
    Br Heart J; 1985 Jul; 54(1):42-7. PubMed ID: 4015915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure.
    Corbalán R; Jalil J; Chamorro G; Casanegra P; Valenzuela P
    Am J Cardiol; 1990 Mar; 65(9):644-9. PubMed ID: 2178384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.
    Anderson JL; Baim DS; Fein SA; Goldstein RA; LeJemtel TH; Likoff MJ
    J Am Coll Cardiol; 1987 Apr; 9(4):711-22. PubMed ID: 3549837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
    Varriale P; Ramaprasad S
    Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Milrinone, a new agent for the treatment of congestive heart failure.
    Hasegawa GR
    Clin Pharm; 1986 Mar; 5(3):201-5. PubMed ID: 3514085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acute effect of an oral "inotropic" placebo on the exercise capacity of patients with chronic cardiac failure.
    Murali S; Uretsky BF; Kolesar JA; Valdes AM; Reddy PS
    Chest; 1988 Aug; 94(2):262-6. PubMed ID: 3396401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic achievements of phosphodiesterase inhibitors and the future.
    Jewitt DE
    Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
    Tommaso CL
    Am J Med; 1986 Feb; 80(2B):36-9. PubMed ID: 3004210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.